The Trump administration on Monday released new guidance for approving customized medicines for patients with rare genetic conditions — treatments the pharmaceutical industry has long considered unprofitable. Under the new "plausible mechanism" pathway, the FDA will consider approving therapies based on evidence they have a biologically plausible mechanism of action, without requiring traditional Phase 2/3 trials. The move is expected to flood the agency with rare disease applications and fundamentally change how bespoke gene therapies reach patients. Critics worry about safety standards; proponents see it as a lifeline for ultra-rare conditions with no other options.
Gilead Sciences is buying Arcellx for $7.8 billion to gain full control of anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR T-cell therapy for relapsed/refractory multiple myeloma. The FDA has already accepted the BLA, with a PDUFA action date of December 2026. The deal reflects Gilead's commitment to expanding its CAR-T portfolio beyond Kite's Yescarta and Tecartus.
Vanda Pharmaceuticals scored FDA approval for BYSANTI (milsaperidone) — its second approval in two months after winning a motion sickness nod. BYSANTI treats bipolar I disorder and schizophrenia, backed by bioequivalence data to Fanapt and over 100,000 patient-years of clinical and real-world use. The approval comes after the FDA rejected Vanda's jet lag treatment Hetlioz in early January.
DeepSeek is expected to announce its fourth-generation AI model, V4, around the Lunar New Year — potentially this week. The release could rattle markets again: when the open-source reasoning model DeepSeek V3 launched in January 2025, the Nasdaq Composite tumbled 3% and Nvidia lost nearly 17% in a single day. According to a senior Trump administration official, V4 was trained on Nvidia's most advanced Blackwell chip — a potential violation of US export controls. Meanwhile, Anthropic and OpenAI have accused DeepSeek of "distillation attacks," effectively stealing proprietary technology from Claude and GPT models. The V4 launch is being watched closely by investors, policymakers, and AI labs alike.
Anthropic has detailed how Chinese AI companies including DeepSeek and MiniMax engage in "distillation attacks" — querying Claude repeatedly to reverse-engineer its capabilities and copy them into cheaper models. OpenAI made similar accusations in January, stating DeepSeek used distillation techniques as part of "ongoing efforts to free-ride on US frontier labs." The practice raises questions about IP theft, export controls, and whether open-weight models can ever be truly protected.
Google's Gemini 3.1 Pro has set a new performance benchmark across reasoning, coding, and multimodal tasks. The timing is deliberate: DeepSeek's V4 is expected imminently, and Google wants to preempt it. OpenAI, meanwhile, is expanding enterprise AI with Frontier Alliances to scale agent deployment. The LLM arms race is now a three-way competition between US labs and a scrappy Chinese upstart.
Researchers have developed a drug-controllable CAR-T system that acts as an on/off switch at the level of cell–cell contact, rather than inside the cell. Unlike earlier approaches that block signaling, degrade CAR components, or induce cell death, this switch preserves the CAR-T cells for continued treatment — offering enhanced safety without requiring their sacrifice. The technology could address one of the biggest challenges in CAR-T therapy: managing severe toxicities like cytokine release syndrome (CRS) without permanently losing therapeutic cells. If validated, this could become the standard for next-generation CAR-T products.
The emergence of CAR-T therapies and bispecific antibodies has redefined the treatment landscape for relapsed/refractory multiple myeloma, providing new options for heavily pretreated patients. Oncologists now face complex sequencing decisions: CAR-T for patients fit for apheresis and bridging therapy, or bispecifics for those needing off-the-shelf options. Alternative targets like GPRC5D are emerging as BCMA resistance develops.
CAR-T therapies and bispecific antibodies have transformed treatment for relapsed/refractory DLBCL. The choice hinges on patient fitness, apheresis feasibility, manufacturing timelines, and toxicity tolerance. Bispecifics offer immediacy and repeatability; CAR-T offers one-shot curative potential. Mechanistic differences are also key: CAR-T redirects engineered autologous T cells, while bispecifics engage endogenous T cells via CD3/BCMA binding.
The Los Angeles Lakers are reportedly exploring a blockbuster trade for a Cleveland Cavaliers center to bolster their roster ahead of the playoff push. Austin Reaves, one of the Lakers' most valuable young assets, is being floated as the centerpiece of a potential deal. The Cavaliers are currently first in the East, but roster shakeups are always possible as teams evaluate their championship windows. Tonight, Knicks face the Cavaliers in Cleveland — a game that could influence trade conversations if injury concerns or performance issues emerge.
The New York Knicks visit the Cleveland Cavaliers tonight in a key Eastern Conference matchup. Both teams are jockeying for playoff seeding, and with trade rumors swirling around Cavs players, tonight's performance could be telling. Also on deck: Thunder vs Raptors (7:30 PM ET) and Lakers vs Magic.
GG Jackson has been tremendous for Memphis lately, and with little competition for touches on a short-handed roster, he has a safe floor and high ceiling. Also trending: Isaiah Huff (Pacers, with Isaiah Jackson dealt), Santos (Warriors, averaging 15-5-4 with 2 stocks per game since late January). Week 18 waiver wire adds are critical for fantasy playoff positioning.
NBC Sports / FantraxHQ / Yahoo Sports / FantasySP2 min
Das Beste, was Wien und Umgebung aktuell an Kinderkultur zu bieten hat: Wo ist Wald? — Ein Stück über den Wald und seine Bewohner in Laut- und Gebärdensprache im Dschungel Wien (läuft bereits, nächste Vorstellungen diese Woche). Die Falter Kinder-Tipps werden wöchentlich aktualisiert und bieten einen Überblick über Theaterproduktionen, Museumsworkshops und Outdoor-Events für Familien. Zusätzlich: Der Kinder- und Jugend-Kultursommer 2026 nimmt noch bis 30. März Bewerbungen entgegen — Kulturschaffende und Vereine können Projekte einreichen.
FALTER Kinder / MeinBezirk / 1000things·Feb 182 min read